R. DeBlasio

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

J. Badger, D. Davar, A. Dzutsev, 2021, Science.

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Simon C Watkins, D. Davar, Joe-Marc Chauvin, 2022, The Journal of clinical investigation.

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

J. Badger, D. Davar, A. Dzutsev, 2022, Nature Medicine.

The Combined Roles of Race/Ethnicity and Substance Use in Predicting Likelihood of Kidney Transplantation

M. Dew, R. DeBlasio, L. Myaskovsky, 2022, Transplantation.

How Can Pharmacists Support STI Prevention and Treatment Among Female Adolescents and Young Adults

R. DeBlasio, Olufunmilola Abraham, M. Rubin, 2017 .

303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results

D. Davar, Joe-Marc Chauvin, R. DeBlasio, 2020 .

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

D. Davar, Joe-Marc Chauvin, R. DeBlasio, 2020, Clinical Cancer Research.